The U.S. Food and Drug Administration (FDA) website published that the tetrahydropyrimidine carboxylic acid (also known as ectoin) independently developed by Freda Biotechnology has successfully passed the DMF filing of the FDA for active pharmaceutical ingredients (API) (DMF filing No.038868), becoming one of the two products of the same type in the world that have passed the FDA API filing.

In the vast field of the food industry, innovation is the inexhaustible driving force for the development of the industry. After unremitting efforts and strict reviews, Freda Biotechnology has officially obtained the food production license (for condiments), marking a solid and far-reaching step forward for Freda in the exploration of food innovation and the condiment sector.

Recently, the official website of the Center for Medical Device Evaluation (CMDE) under the National Medical Products Administration (NMPA) announced that sodium polyglutamate for medical devices, independently developed by Freda Biotechnology, has successfully completed Master File registration (Master File Registration No.M2024350-000). This marks the first Master File registration for such product in China.

Recently, the U.S. Food and Drug Administration (FDA) announced on its official website that natamycin, developed independently by Freda Biotech, has successfully obtained U.S. FDA Drug Master File (DMF) certification (DMF No. 042063).